Strong association of the HLA-DP6 supertype with childhood leukaemia is due to a single allele, DPB1*0601

Leukemia

Volumn 23, Issue 5, 2009, Pages 863-869

  Taylor, G M ^a   Hussain, A ^a   Verhage, V ^a   Thompson, P D ^a   Fergusson, W D ^a   Watkins, G ^a   Lightfoot, T ^b   Harrison, C J ^c   Birch, J M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DP ANTIGEN; HLA DP6 ANTIGEN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; EXON; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; HAPLOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; LYMPHOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BINDING; SEQUENCE ANALYSIS; SOLID TUMOR; T LYMPHOCYTE ACTIVATION;

EID: 67349284793     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.374     Document Type: Article

References (50)

1. Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB et al. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 1997; 94: 13950-13954.
2. Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 1999; 354: 1499-1503.
3. Greaves MF, Wiemels J. Origins of chromosomal translocations in childhood leukaemia. Nature Rev Cancer 2003; 3: 639-649.
4. McHale CM, Smith MT. Prenatal origin of chromosomal translocations in acute childhood leukaemia: Implications and future directions. Am J Hematol 2004; 75: 254-257.
5. Mori H, Colman SM, Xiao Z, Ford AM, Healy LE, Donaldson C et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Nat Acad Sci 2002; 99: 8242-8247.
6. Wiemels JL, Ford AM, Van Wering ER, Postma A, Greaves M. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood 1999; 94: 1057-1062.
7. MacKenzie J, Gallagher A, Clayton RA, Perry J, Eden OB, Ford AM et al Screening for herpesvirus genomes in common acute lymphoblastic leukemia. Leukemia 2001; 15: 415-421.
8. MacKenzie J, Greaves MF, Eden TO, Clayton RA, Perry J, Wilson KS et al. The putative role of transforming viruses in childhood acute lymphoblastic leukemia. Haematologica 2006; 91: 240-243.
9. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 2006; 6: 193-203.
10. Gustafsson B, Bogdanovic G. Specific viruses were not detected in Guthrie cards from children who later developed leukemia. Pediatr Hematol Oncol 2007; 24: 607-613.
11. O'Connor SM, Boneva RS. Infectious etiologies of childhood leukemia: plausibility and challenges to proof. Environ Health Perspect 2007; 115: 146-150.
12. Pagano JS, Blaser M, Buendia M-A, Damania B, Khalili K, Raab-Traub N et al. Infectious agents and cancer: Criteria for a causal relation. Semin Cancer Biol 2004; 14: 453-471.
13. Nevels M, Täuber B, Spruss T, Wolf H, Dobner T. 'Hit-and-run' transformation by adenovirus oncogenes. J Virol 2001; 75: 3089-3094.
14. Shen Y, Zhu H, Shenk T. Human cytomegalovirus IE1 and IE2 are mutagenic and mediate 'hit-and-run' oncogenic transformation in cooperation with adenovirus E1A proteins. Proc Natl Acad Sci USA 1997; 94: 3341-3345.
15. De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37.
16. Johansson M, DeNardo DG, Coussens LM. Polarized immune responses differentially regulate cancer development. Immunol Reviews 2008; 222: 145-154.
17. Cooke GS, Hill AVS. Genetics of susceptibility to human infectious disease. Nat Rev Genet 2001; 2: 967-977.
18. Martin MP, Carrington M. Immunogenetics of viral infections. Curr Opin Immunol 2005; 17: 510-516.
19. Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK et al. Gene map of the extended human MHC. Nat Rev Genet 2004; 5: 889-899.
20. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994; 76 287-299.
21. Madden DR. The three-dimensional structure of peptide-MHC complexes. Ann Reviews Immunol 1995; 13: 587-622.
22. Hammer J, Sturniolo T, Sinigaglia F. HLA class II peptide binding specificity and autoimmunity. Adv Immunol 1997; 66: 67-100.
23. Taylor GM, Dearden S, Ravetto P, Ayres M, Watson P, Hussain A, et al. UKCCS Investigators. Genetic susceptibility to childhood common acute paediatric lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLADPB1°0201. Hum Mol Genet 2002; 11: 1585-1597.
24. Taylor M, Harrison C, Eden T, Birch J, Greaves M, Lightfoot T et al HLA-DPB1 supertype-associated protection from childhood leukaemia: relationship to leukaemia karyotype and implications for prevention. Cancer Immunol Immunother 2008; 57: 53-61.
25. Taylor GM, Hussain A, Lightfoot TJ, Birch JM, Eden TOB, Greaves MF, on behalf of UKCCS Investigators. HLA-associated susceptibility to childhood B cell precursor ALL: Definition and role of HLA-DPB1 supertypes. Br J Cancer 2008; 98: 1125-1131.
26. De Koster HS, Kenter MJH, D'Amaro J, Luiten RM, Schroeijers WEWM, Giphart MJ et al. Positive correlation between oligonucleotide typing and T-cell recognition of HLA-DP molecules. Immunogenetics 1991; 34: 12-22.
27. Doytchinova IA, Flower DR. In silico identification of supertypes for class II MHCs. J Immunol 2005; 174: 7085-7095.
28. UK Childhood Cancer Study Investigators. The United Kingdom Childhood Cancer Study: Objectives, materials and methods. Br J Cancer 2000; 82: 1073-1102.
29. Harrison CJ, Martineau M, Secker-Walker LM. The Leukaemia Research Fund/United Kingdom Cytogenetics Group karyotype database in acute lymphoblastic leukaemia: A valuable resource for patient management. Br J Hematol 2001; 113: 3-10.
30. Neitzel H. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 1986; 73: 320-326.
31. Rozemuller EH, Eliaou JF, Baxter-Low LA, Charron D, Kronick M, Tilanus MG. An evaluation of a multicenter study on HLA-DPB1 typing using solid-phase Taq-cycle sequencing chemistry. Tissue Antigens 1995; 46: 96-103.
32. Goodridge D. User Guide Assign-SBT version 3.2.7: Conexio Genomics. http://www.conexio.iinet.net.au/, 2004.
33. Reinders J, Rozemuller EH, van Gent R, Arts-Hilkes YHA, van den Tweel JG et al. Extended HLA-DPB1 polymorphism: An RNA approach for HLA-DP1 typing. Immunogenetics 2005; 57: 790-794.
34. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Human Heredity 2008; 66: 87-98.
35. Diaz G, Amicosante M, Jaraquemada D, Butler RH, Guillen MV, Sanchez M et al. Functional analysis of HLA-DP polymorphism: A crucial role for DPβ residues 9,11,35,55,56,69,84-87 in T cell allorecognition and peptide binding. Int Immunol 2003; 15: 565-576.
36. Rossman MD, Stubbs J, Lee CW, Argyris E, Magira E, Monos D. Human leukocyte antigen class II amino acid epitopes. Susceptibility and progression markers for beryllium hypersensitivity. Am J Crit Care Med 2002; 165: 788-794.
37. McCanlies EC, Kreiss K, Andrew M, Weston A. HLA-DPB1 and chronic beryllium disease: A HuGE review. Am J Epidemiol 2003; 157: 388-398.
38. Ueki A, Isozaki Y, Kusaka M. Anti-caspase-8 autoantibody response in silicosis patients is associated with HLA-DRB1, DQB1 and DPB1 alleles. J Occup Health 2005; 47: 61-67.
39. Rihs HP, Conrad K, Mehlhorn J, May-Taube K, Welticke B et al. Molecular analysis of HLA-DPB1 alleles in idiopathic systemic sclerosis patients and uranium miners with systemic sclerosis. Int Arch Allergy Immunol 1996; 109: 216-222.
40. Ottman OG, Nocka KH, Moore MA, Pelus LM. Differential expression of class II MHC antigens subpopulations of human haemopoietic progenitor cells. Leukemia 1988; 2: 677-686.
41. Labuda D, Krajinovic M, Sabbagh A, Infante-Rivard C, Sinnett D. Parental genotypes in the risk of a complex disease. Am J Hum Genet 2002; 71: 193-197.
42. OMIM: Online Mendelian Inheritance in Man. http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?db=OMIM [first accessed April 2007].
43. Nagata T, Weiss EH, Abe K, Kitagawa K, Ando A, Yara-Kikuti Y et al. Physical mapping of the retinoid X receptor B gene in mouse and human. Immunogenetics 1995; 41: 83-90.
44. Rajsbaum R, Fici D, Fraser PA, Flores-Villanueva PO, Awdeh ZL. Polymorphism of the human retinoid X receptor β and linkage disequilbrium with HLA-DPB1. Tissue Antigens 2001; 58: 24-29.
45. Rajsbaum R, Fici D, Boggs DA, Fraser PA, Flores-Villanueva PO, Awdeh ZL. Linkage disequilibrium between HLA-DPB1 alleles and retinoid X receptor β haplotypes. Hum Immunol 2002; 63: 771-778.
46. Grenningloh R, Gho A, di Lucia P, Klaus M, Bollag W, Ho I-C et al. Cutting Edge: Inhibition of the retinoid X receptor (RXR) blocks T helper 2 differentiation and prevents allergic lung inflammation. J Immunol 2006; 176: 5161-5171.
47. Stephenson CB, Rasooly R, Jiang X, Ceddia MA, Weaver CT, Chandraratna RAS et al. Vitamin A enhances in vitro Th2 development via retinoid X receptor pathway. J Immunol 2002; 168: 4495-4503.
48. Wen W, Shu XO, Linet MS, Neglia JP, Potter JD, Trigg ME et al. Allergic disorders and the risk of childhood acute lymphoblastic leukemia. Cancer Causes Control 2000; 11: 303-307.
49. Schüz J, Morgan G, Böhler E, Kaatsch P, Michaelis J. Atopic disease and childhood acute lymphoblastic leukemia. Int J Cancer 2003; 105: 255-260.
50. Hughes AM Lightfoot T, Simpson J, Ansell P, McKinney PA, Kinsey SE, Mitchell CD et al. Allergy and risk of childhood leukaemia: results from the UKCCS. Int J Cancer 2007; 121: 819-824.